Capillary and Venous Blood Sampling Devices Industry - Regional Synopsis
North America Market Analysis
North America in capillary and venous blood sampling devices market is set to dominate over 37.2% revenue share by 2037, owing to the increasing incidence of chronic diseases and innovations in blood sampling techniques. Hypertension, diabetes, and anemia have become prevalent ailments that have led to the need for blood sampling procedures that are less invasive and more comfortable for the patient. As per CDC in 2023, more than two thirds of the adult population in the U.S. has at least one chronic disease, and slightly less than half of the adults have two or more. The increasing proportion of the elderly and the growth of preventive healthcare also contribute to the market and force companies to develop new blood sampling technologies.
Technological innovation in blood sampling devices is on the rise in the U.S., with much emphasis being placed on reducing the level of discomfort for the patient while at the same time increasing precision. The FDA’s simplified approval procedures are facilitating the fast-paced commercialization of new blood collection technologies. In April 2024, Drawbridge Health obtained the FDA 510(k) clearance for a NanoDrop blood collection device that can be used without the prescription of a healthcare professional. The dual nano-needle technology enhances Drawbridge’s OneDraw system, an FDA Class II device for glycated hemoglobin (HbA1c) testing to transform long-term glucose monitoring and enhance patient compliance with chronic disease management.
The capillary and venous blood sampling devices market in Canada is progressing due to the government support in the healthcare sector and innovations in the blood sampling technology. The country’s universal healthcare system is promoting the use of advanced diagnostic facilities, which makes it easier to diagnose chronic diseases. New collaborations between healthcare suppliers and diagnostic companies are pushing for the development of automated and non-contact blood sampling systems. In 2023, diagnostic centers of Canada noted an uptick in capillary blood sampling for home-based remote patient monitoring to improve diagnosis for patients in rural and other hard-to-reach areas.
Asia Pacific Market Statistics
APEJ capillary and venous blood sampling devices market is set to register more than 7.4% growth from 2025 to 2037, due to the growing healthcare facilities, the growing prevalence of chronic diseases, and the development of point-of-care diagnostics. High population density, rising incidence of geriatric population, and government support towards healthcare are some factors that have led to the use of automated and patient-friendly blood collection devices in the region. Currently, companies in APEJ are targeting painless, disposable, and anti-infection blood collection solutions for patients in healthcare facilities, hospitals, and homes. Technological collaborations are also increasing the access to sophisticated sampling devices within developing countries.
The capillary and venous blood sampling devices market in India is rising owing to increased healthcare consciousness, increasing demand for efficient diagnostic equipment, and new innovations. The country is experiencing a change in blood sample collection practices that is less invasive and more patient-centered, especially in pediatric, geriatric, and diabetes patients. In December 2024, Metropolis Healthcare Limited launched the UltraTouch Push Button Blood Collection Set (PBBCS) which was the first of its kind in India. This thin-needle innovation decreases the pain associated with the needle insertion and thereby improving patient satisfaction, especially in cases with children, the elderly, and first-time users, which is a sign of India’s progress in patient-centric healthcare solutions.
The capillary and venous blood sampling devices market in China is rapidly growing due to the stringent government guidelines, rising healthcare expenditure, and growth in the diagnostic segment. The National Medical Products Administration (NMPA) is responsible for regulating medical devices, drugs and cosmetics, with a stringent clinical trial and documentation process before products can be approved for use. These stringent measures help ensure high safety, performance and quality standards for new blood collection devices. The increased healthcare reforms by the government and the localization of medical device manufacturing are creating domestic innovation for cost-efficient and technologically advanced blood sampling solutions for a growing healthcare capillary and venous blood sampling devices market.
